Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

FDA greenlight for esketamine sheds light on ketamine’s potential

In March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of ketamine for use as a treatment for depression. Billed as the most exciting antidepressant in decades, the drug has an entirely new mechanism of action. So what does esketamine offer, and why is the FDA so sure the benefits outweigh the risks?

Free download worth over $5000
Download our 2018 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global technology, media and telecoms
Close
Close
Close

Go Top